Affordable Access

deepdyve-link
Publisher Website

Dihydroceramide desaturase 1, the gatekeeper of ceramide induced lipotoxicity.

Authors
  • Rodriguez-Cuenca, S1
  • Barbarroja, N2
  • Vidal-Puig, A3
  • 1 Metabolic Research Laboratories, Wellcome Trust MRC Institute of Metabolic Science, Addenbrooke's Hospital, University of Cambridge, Cambridge, UK. Electronic address: [email protected]
  • 2 IMIBIC, Reina Sofia University Hospital, Cordoba, Spain. Electronic address: [email protected] , (Spain)
  • 3 Metabolic Research Laboratories, Wellcome Trust MRC Institute of Metabolic Science, Addenbrooke's Hospital, University of Cambridge, Cambridge, UK; Wellcome Trust Sanger Institute, Hinxton, UK. Electronic address: [email protected]
Type
Published Article
Journal
Biochimica et Biophysica Acta
Publisher
Elsevier
Publication Date
Jan 01, 2015
Volume
1851
Issue
1
Pages
40–50
Identifiers
DOI: 10.1016/j.bbalip.2014.09.021
PMID: 25283058
Source
Medline
Keywords
License
Unknown

Abstract

The pathogenic relevance of sphingolipid metabolism is increasingly being recognised. Here we elaborate on a new player within the sphingolipid field: the degs1 enzyme, a recently discovered enzyme that catalyses the final step in the de novo biosynthesis of ceramides controlling the step from dihydroceramides to ceramides. Here, we describe its function and dysregulation by factors such as oxidative stress, hypoxia and inflammation and provide evidence indicating that dihydroceramides constitute a biologically active molecule from the sphingolipid family with certain differential characteristics with respect to its delta-4 unsaturated counterparts, the ceramides. Finally we present pathophysiological scenarios characterised by specific increases in dihydroceramide that challenge the concept that "all ceramides species are the same". This article is part of a Special Issue entitled Linking transcription to physiology in lipodomics.

Report this publication

Statistics

Seen <100 times